Insight Kids: Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
Study Details
Study Description
Brief Summary
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy. Furthermore, this study will add clinical data originating from clinical investigation in a special population, i.e. children and adolescents of ages 2 - 17 years , to the existing clinical data of the ACCU-CHEK Insight insulin pump.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Continuous Subcutaneous Insulin Infusion (CSII) Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age |
Device: Accu-Chek Insight Pump System
Continuous subcutaneous insulin infusion pump
|
Outcome Measures
Primary Outcome Measures
- Percentage of Children and Adolescents of Ages 2 to 17 Years Reaching an HbA1c target of <7.5% [26 weeks]
This HbA1c target of <7.5% proportion is statistically tested against a proportion of 25%, composed of the anticipated population proportion of 15% of children and adolescents using multiple daily insulin injections plus a safety margin of 10%.
Secondary Outcome Measures
- Score on Insulin Pump Questionnaire [26 weeks]
- Score on Diabetes Treatment Satisfaction Questionnaire (DTSQ) [26 weeks]
- Score on Pediatric Quality of Life Inventory (PedsQL) [26 weeks]
- Change from Baseline in HbA1c [26 weeks]
- Change from Baseline in Blood Glucose [26 weeks]
- Number of Subjects, Who Report a Diabetes-Related Adverse Event (i.e., Symptomatic Hypoglycemia, Severe Hypoglycemia, Diabetic Ketoacidosis) [26 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Children and adolescents at least 24 months of age, and not more than 17 years of age at screening
-
Diagnosed with type 1 diabetes
-
Diagnosis of type 1 diabetes established > 6 months before study start if >5 years of age
-
Indication for insulin pump therapy according to local guidelines
-
Subject's most recent HbA1c is equal or above 7.0% (53.0 mmol/mol) - measured at last assessment before screening within the past 2 months prior to the Baseline Visit into the study
-
Willingness to use automated bolus advice obtained from the Accu-Chek Insight diabetes therapy system during the study
-
Willingness and ability to participate and comply with study procedures
Exclusion Criteria:
-
Disease or condition that in the opinion of the investigator is likely to affect compliance or the ability to complete the study
-
Not willing or able to start insulin pump therapy
-
Not willing to self-measure blood glucose at least four times daily
-
Significantly impaired awareness of hypoglycemia
-
More than one hospitalization for severe hypoglycemia during the last 12 months
-
History of recurrent ketoacidosis during intensive insulin therapy
-
Known strong plaster incompatibility and/or allergy
-
Unstable chronic disease other than diabetes (e.g. impaired hepatic function, impaired renal function, impaired cardiac function, uncontrolled vascular complications) and any other condition interfering with the study procedures, as per Investigator´s discretion.
-
If on antihypertensive, thyroid, anti-depressant or lipid-lowering medication, lack of stability on the medication for the past 2 months prior to the Baseline Visit in the study
-
Chronic use of steroids in adrenal suppressive doses, other immuno-modulatory medication or chemotherapy
-
Prescription medications other than insulin interfering with diabetes management
-
Acute illness or abnormality (e.g. impaired vision, impaired motor function, acute pain) at the time of screening interfering with study procedures, affecting compliance, or the ability to complete the study as per Investigator´s discretion
-
Either pregnant or breastfeeding
-
Drug dependency
-
Dependency on sponsor or Investigator (e.g. co-worker or family member)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University Graz | Graz | Austria | 8036 | |
| 2 | Universitatsklinik fur PadiatrieI, Padiatrische Diabetologie und Endokrinologie | Innsbruck | Austria | 6020 | |
| 3 | Medical University of Vienna-Dept of Pediatrics | Vienna | Austria | 1090 | |
| 4 | Kinderkrankenhaus auf der Bult | Hannover | Germany | 30173 | |
| 5 | Gemeinschaftspraxis für Kinder- und Jugendmedizin | Herford | Germany | 32051 | |
| 6 | Practice for Pediatric and Adolescent Diabetology | Munster | Germany | 48155 | |
| 7 | Universitatsklinikum Tubingen | Tubingen | Germany | 72076 | |
| 8 | Birmingham Children's Hospital Foundation Trust | Birmingham | United Kingdom | B46NH | |
| 9 | St. James's University Hospital | Leeds | United Kingdom | LS97TF |
Sponsors and Collaborators
- Hoffmann-La Roche
- Roche Diabetes Care GmbH
Investigators
- Study Director: Cosima Rieger, Dr., Roche Diabetes Care GmbH
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RD002177